Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.37 USD
-0.02 (-6.12%)
Updated Aug 13, 2024 03:59 PM ET
Pre-Market: $0.37 0.00 (0.84%) 9:24 AM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.37 USD
-0.02 (-6.12%)
Updated Aug 13, 2024 03:59 PM ET
Pre-Market: $0.37 0.00 (0.84%) 9:24 AM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will RedHill Biopharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor RedHill Biopharma
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
by Zacks Equity Research
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
by Zacks Equity Research
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
How to Screen for the Best Growth Stocks
by Tracey Ryniec
Wouldn't you like a list of the top growth stocks right now?
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
High Fiber Solutions Revenues to Aid Zayo (ZAYO) Q4 Earnings
by Zacks Equity Research
Strong momentum in Fiber Solutions business and solid inorganic growth are likely to drive Zayo's (ZAYO) fiscal Q4 revenues although margin woes remain a concern.
What's in the Offing for Keysight (KEYS) in Q3 Earnings?
by Zacks Equity Research
Keysight's (KEYS) focus on launching new solutions for growth markets like 5G, IoT, next-generation wireless, high-speed datacenters and automotive & energy bodes well for its top-line.
What's in the Offing for Pure Storage (PSTG) in Q2 Earnings?
by Zacks Equity Research
Pure Storage (PSTG) is rapidly gaining traction in the flash storage market, which is evident from its expanding customer base.
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
by Zacks Equity Research
Small drugmakers, in general, are having a rather poor year, the principle reason being failure of key pipeline candidates in pivotal studies.
RedHill Gets Two New Patents for Crohn's Disease Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
RedHill Biopharma (RDHL): Moving Average Crossover Alert
by Zacks Equity Research
RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
RedHill Biopharma (RDHL) was a big mover last session, as the company saw its shares rise more than 10% on the day.
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
by Zacks Equity Research
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
5 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Company News for April 05, 2017
by Zacks Equity Research
Company News for April 05, 2017
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.